行情

CRTX

CRTX

Cortexyme
NASDAQ

实时行情|Nasdaq Last Sale

53.43
+1.02
+1.95%
交易中 13:27 02/27 EST
开盘
51.89
昨收
52.41
最高
56.30
最低
50.00
成交量
9.31万
成交额
--
52周最高
73.84
52周最低
19.35
市值
13.90亿
市盈率(TTM)
-33.1164
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测CRTX价格均价为81.20,最高价位193.00,最低价为14.00。

EPS

CRTX 新闻

更多
  • Cortexyme up 4% on potential accelerated timeline for lead candidate
  • Seeking Alpha - Article · 02/13 16:58
  • Cortexyme Offers Regulatory Update For COR388 Program In Alzheimer's
  • Benzinga · 02/13 13:09
  • Cortexyme Provides Regulatory Update for COR388 Development Program in Alzheimers Disease
  • Business Wire · 02/13 13:00
  • Cortexyme Announces Closing of $125 Million Private Placement
  • Business Wire · 02/10 21:05

所属板块

生物技术和医学研究
-1.12%
制药与医学研究
-0.44%

热门股票

代码
价格
涨跌幅
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

CRTX 简况

Cortexyme, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on providing disease-modifying therapeutics to treat Alzheimer’s and other degenerative diseases. The Company is focused on a infectious pathogen tied to neurodegeneration in humans and animal models. The Company’s lead drug candidate, COR388, is an orally-administered, brain-penetrating small molecule gingipain inhibitor designed for the treatment of Alzheimer’s disease. COR388 is designed to target an upstream driver of multiple Alzheimer’s pathological pathways, including amyloid beta production, inflammation and neurodegeneration, in contrast to mechanisms of action targeting downstream effects, such as amyloid plaques and tau tangles.
展开

微牛提供Cortexyme Inc(NASDAQ-CRTX)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的CRTX股票新闻,以帮助您做出投资决策。